

## Index

### **a**

- absolute bioavailability 28
- absorption, distribution, metabolism and excretion of a compound (ADME) 8, 9, 19, 43, 59, 135, 144, 261, 271
- accelerated pathways 188–190, 196
- active pharmaceutical ingredient (API)
  - patent 297
  - preclinical development and clinical phase 1 107–108
  - preclinical development and clinical phase 2 111
- active receptors 16
- Active Substance Master File (ASMF) 347
- adaptive trials design 171–172
- adverse effects 10, 69, 81, 82, 84–85, 87, 89, 91, 93, 125, 211, 375
- advisory boards 174
- Advisory Committee (AC) meeting 197
- agile development process 373–374
- agonism 15–18
- agonists 11, 16–17, 168
- alliance management 323, 331–332
- analysis populations 163, 166
- analytical biomarker validation 66
- analytical development
  - preclinical development and clinical phase 1 109–110
  - preclinical development and clinical phase 2 111
- animal experimentation 37
  - 3 R principles of 91
  - animal species selection 89
- antagonism 15–18
- antagonist 16–17, 24
- anti-cancer drugs 87, 93–94
- antigen content 385–386
- antigenic drift 381
- area under the concentration curve (AUC) 28–29
- artificial intelligence 64, 78, 135, 261, 376
- Arzneimittelmarkt Neuordnungsgesetz (AMNOG) 247
  - drug prices in Germany 251–252
  - study design 254
  - success in German market 253
- assay
  - costs for 48
  - of pharmacological 47–48
  - robustness of 48
- assessment report (AR) 184, 198
- assessment table 156
- asset shaping stage, MA&P 238–239
- ATP binding cassette 25, 49, 52
- autophosphorylation 13

### **b**

- back-loaded 320
- back or forward and backward translation 129–132
- bankruptcy 341
- basic patents 262, 296, 311, 313
- basket trials 173

- bedside to bench or backward translation 130–132
  - bench to bedside 121, 127, 129–131, 134
  - benchmark products 211, 219
  - benefit assessment 84, 146, 179, 233, 247–256
  - biased (hypothesis-driven) approach 68
  - biliary elimination 27
  - bioavailability (BA or F) 21, 28, 30–31, 82, 102
  - biochemical assays 47
  - biochips 366
  - biologics 81, 100, 104, 116, 167, 186, 187, 196–198
  - Biologics License Application (BLA) 116, 180, 196–197
  - biomarker(s) 64
    - development 65
    - drug development 73–75
    - modalities 69–73
    - use cases 75–77
    - validation 66
  - biomarker qualification program (BQP) 74–75
  - biopharmaceutical classification system (BCS) 102–103
  - biopharmaceutical drug development 2–4
  - biopharmaceutical industry
    - FTO issues in 300–301
    - intellectual property protection in 294–295
    - regulatory environment 177–181
  - biopharmaceutical innovation 1–5
  - biotech funding
    - exit options 342–343
    - seed funding 335–336
    - series A 336–339
    - series B 339–341
    - series C 341–342
    - venture debt 341
  - biotechnology patents 307–308
  - black-box 5, 255
  - blood-brain barrier (BBB) 21–22
  - blood transfusion 365
  - board of directors 338, 342
  - brand differentiation 236
  - budget impact 230–231, 243
  - Business Development & Licensing (BD&L) 318
    - alliance management 331–332
    - Case-in-point 1 326–327
    - Case-in-point 2 327
    - Case-in-point 3 328–329
    - Case-in-point 4 330
    - Case-in-point 5 331
    - collaborations, types 318–319
    - commercial or distribution partnerships 320–321
    - due diligence 327–328
    - evaluation process 324–326
    - letter of intent 329–330
    - licensing agreements 319–320
    - negotiation and contract closure 330–331
    - other types of agreements 321–322
    - research collaborations 321
    - structured approach 322–324
    - tech transfer agreements 322
    - term sheet 329, 330
  - business model 257, 305, 317, 318, 332, 336
    - of Prionics 312
  - business plan 139–140, 142, 333, 336–337
- C**
- $C_{\max}$  28, 29, 169
  - $C_{\text{trough}}$  28, 29
  - candidate list 346
  - candidate selection 39, 56, 58–60, 92, 140, 144
  - CANTOS study 132
  - carcinogenic potential 87, 95
  - Case-in point A 192
  - Case-in point B 193
  - Case-in-point 1, BD&L 326–327
  - Case-in-point 2, BD&L 327
  - Case-in-point 3, BD&L 328–329
  - Case-in-point 4, BD&L 330

- Case-in-point 5, BD&L 331
- CD28 agonist 168
- cell death 14, 146
- cellular assays 47, 55
- cellular biomarkers 71
- cellular pathology 8
- cellular test systems 42
- chemical antagonists 17
- Chemical Genomics 42–43
- chemical libraries 52
  - compounds in 53–54
  - DNA-encoded chemical libraries 54–55
- chemical target validation 42–43
- chemistry, manufacturing and controls (CMC) 181, 182
  - biopharmaceutical classification system 102–103
  - morphology and polymorphism 105–106, 107
  - NDA submission 116
  - physico-chemical characteristics 101–102
  - stability investigations 104, 105
  - steps to product launch 116
  - transition from research to development 100–101
- chemoluminescence measurement 48
- classical forward translation 129–130, 134
- clearance (CL), of compound 27–28
- clinical biomarker validation 67
- clinical chemistry 361, 363–365, 372
- clinical development plan (CDP) 81, 146, 166
- clinical development, stages of 154
- clinical drug development
  - definition and framework 152
  - stages of 152–155
- clinical evaluation 146, 180, 208, 211, 214, 217, 219
- clinical studies
  - graphical study design 156–160
  - schedule of activities 156–160
  - written subject information 156
- clinical study protocol (CSP) 155–156
- clinical trial(s)
  - assessing treatment effects in 164
  - basic framework and elements for 155
  - design elements of 162
  - logistic aspects of 163
  - operational activities and roles in 165
  - purposes of 160
- clinical trial application (CTA) 110, 111, 166, 180, 184–185, 260–261
- clinical workflow 366–367
- coagulation tests 364–365
- COGs-plus model 320
- commercial or distribution partnerships 320–321
- commercial risks 272
- common technical document (CTD) 112, 116, 179, 182–185, 194
- comparative products 211
- comparative/incremental health benefit 230
- Competent Authority (CA) 110, 372
- competitive antagonists 17
- complaint handling and corrective and preventive action (CAPA) 371
- composite biomarker 67
- conditional reimbursement 241
- Confidentiality Agreement (CDA) 324, 327
- confirmatory phase 1 126, 143, 148, 194, 261
- continuous patent portfolio management 313
- contract closure 317, 322, 327–328, 330–331
- cost benefit analysis (CBA) 225, 233, 286
- cost planning 271–272
- cost utility analysis (CUA) 225, 233
- cost-effectiveness 4, 230–232, 235, 239, 241, 258, 267
- cost-effectiveness analysis (CEA) 225, 233
- cost-minimisation analysis (CMA) 234
- country strategy 313

- coverage with evidence development (CED) 241
  - COVID-19 pandemic 166–167
  - critical material attributes (CMA) 113
  - critical process parameters (CPP) 113
  - critical quality attributes (CQA) 113
  - cross-sectional biomarker 68
  - customer requirements 211–212, 216, 219
  - cytochrome P450 (CYP) enzymes 20, 23–25, 27
- d**
- data mining 102, 131, 132, 134
  - data monitoring committee (DMC) 172, 174
  - data safety and monitoring boards (DSMB) 174
  - 74-Day letter 197
  - 120-Day safety report 197
  - de novo classification 371
  - de-novo drug design approach 51
  - death domains 14
  - death receptors 14
  - decentralised procedure (DP) 198
  - decision making process 140, 231
  - descriptive biomarker 68
  - design and development journal 216
  - design and development log 216
  - design and development plan (DDP) 140–141, 144, 212–213
  - design and development validation 219–222
  - design and development verification 218
  - design change 216, 217
  - design freeze 217
  - design input 216–219
  - design output 216–218
  - design requirements 216
  - design specifications 216
  - design validation 217
  - design verification 217, 219
  - diagnostic biomarker 65, 67, 69, 74
  - digital biomarkers 63, 65, 67, 73, 78
  - digitalization 166–167
  - digitization
    - and artificial intelligence 376
  - direct effect 11
  - disease-related biomarker 68
  - DNA-encoded chemical libraries (DEL libraries) 54–55
  - dose limiting toxicities (DLTs) 146, 168
  - dose-range finding studies (DRF) 31, 33, 92, 180
  - dose-ranging studies 170–171
  - dose-response relationship 18
  - dosing regimen 27, 82, 120, 135
  - Dossier preparation 194, 254
  - drug candidates 38–40, 45, 53–60, 81–83, 86, 89, 97, 100, 102–103, 122, 125, 140, 141, 143–147, 180–181, 258, 261–262, 272
  - drug development
    - implications 18
    - for orphan/rare diseases 187–188
  - drug development pathway/process (DDP) 31, 33, 69, 74, 82, 89, 119–135, 139–144, 150, 212–213, 219–221, 240
  - drug discovery 38–40, 259, 261
    - and development practice 128
    - pharmaco-genetic links to phenotype 41
    - phenotypic screening 41
    - target and its pathway(s) 41
  - drug formulations 104
  - drug marketing authorisation 238
  - Drug Master File (DMF) 347–348
  - drug prices 242
    - in Germany 251–252
  - drug product
    - life cycle management 298
    - loss of exclusivity (LoE) 299–300
    - preclinical development and clinical phase 1 108–109
    - preclinical development and clinical phase 2 111
    - regulatory data protection 299
  - drug projects 258–260, 273–274, 276, 278
  - market 122

- drug purchasing 228–229
- drug-related biomarker 68
- drug repurposing 128
- drug safety 56, 331
  - preclinical evaluation 39
- Dual Blade Cutter 351
- due diligence 317, 323–325, 327, 328, 340
- dynamic biomarker 68
- e**
- early drug development phase 126
- early patient access 240
- efficacy profile 19, 141
- efficacy studies 130, 171
- embryo-fetal development 94–95
- end-of-phase (EoP) 2 meetings 181
- endpoint adjudication committees (EAC) 174
- enzyme-linked immunosorbent assay (ELISA) 71, 77
- enzymes 14
  - activation 14, 15
  - associated receptors 12–14
  - inhibition 15
- equivalent devices 211
- EUnetHTA 185, 243
- European Drug Master File (EDMF) 347
- European In Vitro Diagnostic Regulation (IVDR) 372
- European Patent Office 303, 306, 307
- evaluation process, BD&L 324–326
- evidence building stage, MA&P 239
- exit options 342–343
- expiry date, of patent 289, 294
- exploratory phase 1, 126
- expressed sequence tags (ESTs) 307
- external reference pricing (ERP) 234–235
- extracellular signal-regulated kinases (ERK) 13
- f**
- fast switching valves 352, 55
- fee-for-service 321, 338
- financial projections 336–337
- first in human (FIH) trials 86
  - clinical development 167–169
  - data package required for 87
  - large (bio)molecules and oncology compounds 87–89
  - safe starting dose in 93
  - study 76, 169
- first-in-patients clinical trials (Phase 1) 181
- first pass effect (FPE) 19–20, 21, 23, 27
- fluorescence measurements 48
- fluorescence or silver in-situ hybridization (FISH/SISH) 366
- fluorescence resonance energy transfer (FRET) 48
- forward translation approach 126
- forward vs. reverse/back-translation 126–129
- fragment-based drug discovery 49
- freedom-to-operate (FTO) principle 284, 292–294, 300–302, 310, 313
- front-end loading 273, 274
- front-loaded 319
- full agonists 16–17
- functional antagonists 17
- g**
- genetic target validation 42
- genotoxicity 82, 88, 90, 92, 349–350
- genotype-phenotype relationships 123
- Germany, Federal Joint Committee (G-BA) 225, 228, 248, 250, 252, 254–255
- glomerular filtration 22, 25–26
- glomerular filtration rate (GFR) 26
- Go confirmatory development 148–149
- Go First in Human (FIH) decision 144–147
- Go IND decision 145
- Go IND enabling 142–144
- Go Phase 2 decision 148
- Go/No Go First in Human (FIH) 144–146
- Go/No go Phase 2 146–148

G-protein-coupled receptors (GPCRs)  
 11–12, 49, 51  
 graphical study design 156–160  
 guanylyl cyclase activity 12–13

**h**

haematology tests 364, 365  
 health authorities (HA)  
 early consultations with 185  
 pre-submission meetings 194–195  
 review of registration dossiers  
 196–199  
 health economics 231–234, 238  
 health outcomes 230–232, 241, 243  
 health technology assessment (HTA)  
 232  
 committees 228  
 process 233, 234  
 reach 242–243  
 healthcare challenges 226–227  
 hemagglutination inhibition (HI) 384  
 hemagglutinin (HA) 380, 383–385, 387  
 high content screening 48  
 high throughput screening (HTS) 43,  
 45–52, 54, 261  
 histopathology 91, 366  
 homology modelling 50

**i**

imaging biomarkers 70, 72–73  
 immunoblotting 77  
 immunologic memory 379  
 immunological tests 364  
 implementation and adjusting stage,  
 MA&P 239–240  
 in vitro diagnostics (IVD) 345, 357–358,  
 361, 367, 370–372, 374, 376  
 tests 360  
 in-vitro dissolution technique 103  
 incremental budget impact 231, 243  
 indirect effects 11  
 individualized dosing 34  
 influenza vaccines 385  
 acceptability 387–393  
 antigen content 385–386

challenge 383–384  
 formulation 386  
 history 378–383  
 intradermal administration 386–387  
 mechanisms of 384  
 influenza virion 380  
 initial public offering (IPO) 339, 342  
 innovation, pharmaceutical 257  
 innovative valve technology 352  
 Institute for Clinical and Economic  
 Review (ICER) 235, 242  
 integrated development plan (IDP) 166  
 integration technology 353–355  
 integrative & iterative learning cycles  
 128, 134  
 intellectual property department 301  
 intellectual property protection 294–301  
 intellectual property rights 186,  
 282–284, 294, 300  
 intended purpose 204, 208, 216  
 intended use 94, 109, 207–209, 213, 216,  
 219, 294, 371  
 intent-to-treat population (ITT) 163  
 international/external reference pricing  
 (ERP) 235  
 intestinal elimination 27  
 intradermal administration (ID)  
 386–387, 389–393  
 invasive biomarker 68  
 inverse agonists 16  
 Investigational Medicinal Product Dossier  
 (IMPD) 110, 149, 184–185  
 investigational new drug (IND) 110,  
 140, 142–145, 149, 183–185, 188,  
 260, 271, 319, 336, 339  
 investigator's brochure (IB) 166,  
 180–182, 185  
 ion channels 9, 11–12, 44, 47, 380  
 ionotropic receptors 12  
 ISO 10993 346, 349–350  
 ISO 13485:2016 204–205, 212, 216–219

**j**

c-Jun N-terminal kinases (JNK) 13  
 juvenile toxicity 95

**k**

knockout-phenotypes 42

**l**laboratory developed tests (LDTs)  
367–369

laboratory diagnostics

automation 375

clinical chemistry 363–364

clinical workflow 366–367

definition 358–361

digitization and artificial intelligence  
376haematology and coagulation tests  
364–365

histopathology 366

history 362

immunological tests 364

industry 361–362

microbiology 365

molecular diagnostics 365–366

molecular testing 375

personalized/precision medicine 375

point of care testing 375

quality management 367–370

R&amp;D process 373–374

regulatory approval 370–373

test types 358–359

workflow 362–363

laboratory workflow 362–363

LADME scheme (liberation, absorption,  
distribution, metabolism and  
excretion) 19late-stage development phase 100, 120,  
124–126, 320

lead identification process 44–45

lead optimization 37, 38, 41, 51, 54–59,  
101, 127, 261, 270–272

legal manufacturer 206, 207, 214, 372

Letter of Intent (LoI) 329–330, 337

licensing agreements 318–322, 330

Licogliflozin 129, 130

ligand-based virtual screening 50

ligand-binding site 44

ligand-controlled ion channels 11, 12

ligand-(L)-receptor-(R)-interaction 11

loading dose (LD) 22, 29–31

longitudinal biomarker 68

loss of exclusivity (LoE) 299–300, 302

**m**

MABEL approach 93, 94

Madrid Protocol 281, 282

managed entry agreements (MEAs) 235,  
239–242

Mantoux technique 386

manufacturing units 100

market access 227

decision tool for 231–234

gatekeepers 228

trends 242–243

market and competition 336

market entries 237–240

market risks 272

marketing authorisation application  
(MAA) 181, 185, 190, 191marketing authorization 4, 85, 87, 100,  
112–116, 122, 127, 185, 186, 190,  
198, 226, 235, 238, 296–299, 321,  
340

masking proteins 44

Material Transfer Agreement (MTA) 329

matrix protein 2 ectodomains (M2e) 384

maximal safe starting dose 93

maximum tolerated dose (MTD) 144,  
168

mechanistic biomarker 68

mechanistic studies pharmacodynamic  
(PD) effects 7, 31, 68, 69, 74–77,  
127, 129, 130, 145, 152, 169

medical device regulation (MDR)

203–205, 207, 208, 210, 211

essential safety and performance  
requirements 211

medical devices (MD)

design and development 205

design and development validation  
219–222design and development verification  
218

- medical devices (MD) (*contd.*)
- developing 210, 212
  - planning and executing 216–217
  - post-market phase of 214–215
  - product commercialization 206–208
  - product realization 205
  - qualified input from interested parties 212–215
- medical grade plastics (MPG) 345–350
- Michaelis constant (Km) 15
- microbiology 365
- micro-injection system 377, 390, 391
- mid-cycle communication 197
- minimum anticipated biological effect level (MABEL) approach 93, 94
- mission statement 265, 267, 268
- mixed-function monooxygenase 23
- molecular biomarkers 71–72
- molecular diagnostics 365–366
- monoclonal antibodies (mAbs)
- target specificity of 122
- multiple ascending dose (MAD) 153, 158, 168
- mutual recognition procedure (MRP) 198
- n**
- NADPH (nicotinamide adenine dinucleotide phosphate) 23
- NBTS 329–331
- negotiation
- and contract closure 330–331
- net present value (NPV) 143, 259, 275–278, 324, 327, 370
- neuraminidase (NA) 380, 385, 386
- neurotransmitters, transporters for 14
- New Drug Application (NDA) 99, 110, 111, 116–117, 127, 149, 180, 184, 188, 195–197, 260, 261, 271, 319, 336
- next generation sequencing (NGS) 75, 365, 366, 375
- Non-Disclosure Agreement (NDA) 99, 184, 188, 189, 196, 324
- non-competitive antagonists 17
- non-GLP dose-range-finding studies (DRF) 31, 33, 92, 180
- non-invasive biomarker 68
- non-patentable subject matter 285
- non-receptor-mediated effects 14–15
- no-observed-effect-level (NOAEL) 28, 81, 85, 89–91, 93, 168
- Notified Body (NB) 211, 346, 372
- Nuclear Export Protein 380
- numbers-needed-to-treat (NNT) 74
- o**
- oncology trials 173
- oral formulations 28, 102
- oral glucose tolerance test (OGTT) 130
- The Orange Book 300, 302
- Otamixaban 129–130
- outcomes-based agreement (OBA) 241
- outsourcing 163, 311, 313
- p**
- paediatric diseases 186–187
- Paediatric Investigation Plan (PIP) 186, 192, 193, 195
- paediatric study plan (PSP) 186, 192
- parallel indication expansion 128
- partial agonists 16
- patent(s)
- active pharmaceutical ingredient(s) 297
  - in biomedical sciences and industry 306–309
  - enforcement of 313
  - ethics 308–309
  - expiry date of 289
  - how to obtain 286, 287
  - industrial design right 309–310
  - ownership of 286
  - sale of 291
- Patent Cooperation Treaty (PCT) 288, 289
- patent exclusivity 262, 299
- patent protection 288, 294–296, 298–300, 305, 306, 311–313



- for pharmaceutical drug product 296–298
- patent rights 282, 284–292, 294, 314
  - value and use of 291–292
- patent term extensions (PTE) 298–299
- patentability criteria 285–286
- patentable 285, 286, 294, 296, 306–309, 336
- patenting
  - an invention 291
  - procedure 287–291
- pathway biomarkers 75
- patient population 1, 33, 74, 84, 87, 94, 110, 111, 126, 127, 134, 135, 141, 153, 160–161, 170, 173, 181, 188, 190, 203, 207, 209, 210, 232, 233, 238, 239, 241, 248, 250, 254, 261, 268
- patient reported outcomes (PROs) 167
- patient risk sharing agreement 241
- PAT-INFORMED 300, 302
- payers
  - requirement 236
  - and value assessment 229–231
- PCSK9 41, 44, 131–132
  - identification 131–132
- peak-to-trough-ratio 28
- peri-natal development 95
- periodic safety update reports (PSURs) 199
- pharmaceutical phase 8, 9
- pharmaceutical R&D projects 260, 273
- pharmaceutical target 40
- pharmacodynamic (PD) effects
  - mechanistic studies 169
- pharmacodynamics (PD) 7, 9–11, 31, 56, 68, 69, 74–77, 93, 101, 110, 127, 129, 130, 145, 152, 169, 180
- pharmacokinetic-pharmacodynamic (PKPD) modeling 31, 33, 145
- pharmacokinetics (PK) 8, 19
  - absorption 21
  - administration and liberation 19, 21
  - biliary elimination 27
  - characteristics of 33
  - distribution 21–22
  - excretion 25–27
  - information 146
  - intestinal elimination 27
  - metabolism/biotransformation 22–23
  - phase I reaction 23–25
  - pulmonary elimination 27
  - quantitative 27–30
  - renal elimination 25–26
- pharmacological effect 9, 11, 22, 56, 59, 68, 93
- pharmacology
  - drug development, implications for 31–34
  - pharmaceutical phase 8
  - pharmacodynamics 9
  - pharmacokinetics 8
- pharmacovigilance 199, 273, 327, 330, 331, 387
- pharmacovigilance agreement 330, 331
- phase I reaction
  - oxidation 23–24
  - reduction and hydrolysis 24
- phase II reactions 24, 25
- phase III reactions 25
- phenotypic assays 46, 47
- phenotypic screening 41, 51–52, 54, 180
- physiologically based PK (PBPK) models 30, 31
- PK/PD relationships 68, 76
- pKa value 26, 101, 102
- p38 kinases 13
- plasma concentration 22, 26, 27
- plasma protein binding (PPB) 21, 26
- platform technologies 71, 335
- platform trials 173
- point of care testing (PoCT) 375
- polymerase chain reaction (PCR) 54, 55, 365, 366
- polymorphism 24, 25, 41, 68, 104, 105–107
- poor metabolizer (PM) 24
- population PK (PopPK) models 30, 31, 33
- portal vein system 20

- portfolio management 257–278, 305, 311, 313, 319
  - portfolio of therapeutic molecules 335
  - posology 125, 142, 143
  - post launch 255, 373
  - post marketing surveillance 371
  - post negotiation 255
  - post-marketing/real-world evidence (RWE) 128, 241
  - postnatal development 95
  - PPV 369, 370
  - pre-approval inspection (PAI) 116, 197
  - pre-launch strategy 254
  - pre-NDA 195
  - pre-submission meetings 188, 194–195
  - precision medicine 34, 63, 64, 78, 135, 375
  - preclinical development 100, 107–112, 261, 263
  - preclinical development and clinical phase 1
    - active pharmaceutical ingredient 107–108
    - analytical development 109–110
    - drug product 108–109
    - FIH study 110
  - preclinical development and clinical phase 2
    - active pharmaceutical ingredient (API) 111
    - analytical development 111
    - drug product 111
  - preclinical development and clinical phase 3 111–112
  - preclinical safety 60, 82, 83
  - predefined stopping rules 172
  - predictive biomarker 65, 69, 75, 76
  - premarket approval (PMA) 209, 371, 372
  - premarket notification 371
  - price negotiation 243, 247–256
  - price setting 234–237
  - price transparency 242
  - pricing policy 234
  - pricing structure 249–251
  - principal investigator (PI) 156, 174
  - Prionics 305–314
    - business model of 312
  - probability of technical and regulatory success (PTRS) 273, 275, 276
  - prodrugs 20, 21
  - product commercialization 206–208
  - product differentiation 236
  - product label 175, 193
  - product life cycle 206, 218, 247, 318
  - product realization 205, 212, 217–219
  - prognostic biomarker 65, 68, 69
  - project leader 265–267, 270
  - project lifecycle 269, 270, 272
  - project management 258, 263–269, 271, 272, 274, 275, 332, 373
  - project phases 260, 263, 269–272
  - project sponsor 265, 266, 270
  - project team members 266, 267
  - promoting greater transparency 242
  - proof of concept (PoC or cPoC) 1, 73, 76, 101, 110, 120, 121, 123, 125, 126, 133, 135, 141, 143, 153, 169–170, 172, 181, 190, 260, 261, 263, 272, 274, 339
  - proof-of-clinical concept (PoC) 1, 101, 120, 135, 141, 153, 169, 170, 181, 190, 260, 261, 272, 274
  - proof-of-mechanism (PoM) 76, 125, 153
  - protein-protein interactions (PPI) 40, 44
  - pseudo-polymorphs 105
  - pulmonary elimination 27
- q**
- quality agreement 330, 331, 348
  - quality management 367, 370
    - commercial test 367
    - laboratory developed tests 367–369
    - test performance characteristics 369–370
  - quality management system (QMS) 204, 205, 212, 213, 371
  - quality target product profile (QTPP) 113
  - QUALY 232

- quantitative decision making (QDM)  
170
- quantitative pharmacokinetics  
accumulation and loading dose 29–30  
area under the concentration curve 28  
bioavailability 28  
 $C_{\max}$  28  
 $C_{\text{trough}}$  28  
clearance (CL), of compound 27–28  
dosing regimen 27  
half-life 29  
induction and maintenance dose 30  
peak-to-trough-ratio 28  
volume of distribution 29
- r**
- radioactive measurements 48  
raising capital 292, 337  
R&D process, phases  
development 261  
real-world evidence (RWE) 128, 241  
receiver-operating characteristics (ROC)  
curve 67, 69, 370  
receptor antagonists 17  
receptor-mediated effect 14–16  
receptors  
agonism and antagonism 15–18  
with associated tyrosine kinases 13  
with guanylyl cyclase activity 13  
and ion channels 11–15  
serine/threonine kinases 13–14  
recommended phase 2 dose (RP2D) 146  
regenerative medical products (RMPs)  
190  
regenerative medicine advanced therapy  
(RMAT) 188–190  
regulatory affairs (RA)  
before, during and after registration  
193–194  
clinical trial application 184–185  
common technical document 182–183  
in early drug development 179–182  
in late stage drug development  
190–193  
investigational new drug 183–184  
regulatory data exclusivity 299  
regulatory data protection (RDP) 299,  
300  
regulatory stability studies 112–114  
regulatory uncertainties 272  
reimbursement price level 250  
reimbursement process 1, 225, 230,  
236–237, 240, 249–251  
relative bioavailability 28  
renal elimination 25–27  
reporting member state (RMS) 184  
reproducibility crisis 123  
reproduction effect 82  
reprotoxicology 94  
research collaborations 318, 319, 321,  
330  
response biomarker 68, 69  
restriction of certain hazardous  
substances (RoHS) 346  
consistency of formulation 347–348  
ISO 10993, 349–350  
security of supply 348  
return of investment (ROI) 143, 276,  
278, 339  
risk adjusted net present value (rNPV)  
143, 276, 277  
risk-adjusted or expected NPV (rNPV or  
eNPV) method 276  
risk assessment 3, 18, 60, 83–85, 87, 89,  
90, 92, 94, 96, 142, 143, 182  
risk benefit assessment 146, 179  
risk management 166, 195, 204, 208,  
209, 214, 258, 269, 272–274  
RNA viruses 380  
role, project leader 267
- S**
- safety and performance requirements  
211, 216, 218  
safety biomarker 69  
safety margins 28, 33, 34, 90, 91, 127, 145  
safety pharmacology 82, 87, 88, 92  
safety population (SP) 163  
safety window 84  
safety/tolerability profile 141

- Sakigake 190
  - sample size calculation 156, 160–161
  - sampling rules 172
  - seed financing 335
  - sensors 73, 78, 166–167
  - serendipity 128, 129, 132–134
  - series A financing
    - alternatives to venture financing 338–339
    - team building 338
    - valuation 338
  - signal transduction 12–14, 44
  - Sildenafil 133–134, 236
  - single ascending doses (SAD) 168
  - Smad proteins 14
  - small interfering RNA (siRNA) 42, 43, 306
  - small-scale first-in-human (FIH) 86–89, 94, 107, 108, 110, 144–146, 168, 169, 181
  - Special Protocol Assessment (SPA) 192
  - Spider Diagrams 58
  - stage gate process 278, 373, 374
  - standard of care (SOC) 112, 141, 160, 170, 238, 324
    - product 324
  - static biomarker 68
  - steering committees (SC) 174, 268
  - stepwise approach 328
  - structure-activity relationships (SAR) 45, 49, 51, 53, 92
  - structure-based drug design (SBDD) 49
    - focused screen 49
    - fragment-based drug discovery 49
  - structured approach 264, 322–324
  - study design 91, 95, 156–162, 171, 172, 190, 192, 254
  - substances of very high concern (SVHC) 346
  - substrate excess 15
  - substrate saturation 15
  - supplementary protection certificates (SPC) 186, 299
  - surrogate biomarker 65, 69, 75
  - susceptibility/risk biomarker 69
- t**
- target cost of goods (COGs) 142, 146, 320, 328
  - target identification 37, 40, 127, 261, 270
    - sources for 41
  - target marketing profile (TMP) 142
  - target organs 82, 90, 92
  - target out-licensing profile (TOP) 142, 143
  - target product profile (TPP) 56, 58, 108, 113, 125, 141–142, 146, 150, 153, 166, 170, 268, 277, 324, 326, 327
  - target protein
    - preventing formation of 43
  - target validation 42
    - chemical 42, 43
    - genetic 42
  - team building 338
  - tech transfer agreements 318, 322
  - technical risks 272
  - temporary project 263
  - Term Sheet (TS) 327, 329–330, 333, 334, 337, 340
  - therapeutic drug monitoring 34, 363
  - therapeutic index (TI) 18, 29, 38, 81, 84–85, 270
  - therapeutic range, of substance 18, 22, 143
  - therapeutic reference pricing (TRP) 234–235
  - time planning 271
  - time-resolved fluorescence (TRF) 48
  - top down approach 326
  - toxicological
    - late-stage drug development 94–96
    - for safety evaluations 85–89
  - toxicological framework 83–84
  - toxicological project
    - stage of development 92–93
  - toxicology 1, 5, 81–97, 126, 144, 168, 180, 182, 184, 328
  - trade secret 282, 283, 286, 310, 319, 347
  - translational medicine (TM)
    - back or forward and backward translation 129–132

- backward translation 130–132
  - bedside to bench 130–132
  - bench to bedside 129–132
  - classical forward translation 129–130
  - definitions and history 120–121
  - failed translation 122–123
  - forward vs. reverse/back-translation 126–129
  - learning and confirming paradigm 124–126
  - models predictivity 123–124
  - serendipity 132–134
  - translatability gap 123–124
  - transporters 7, 10, 11, 14, 25–27, 44, 47
  - tubular reabsorption 25, 26
  - tubular secretion 25, 26
  - tumor necrosis factor (TNF) receptors 12, 14, 128
  - turnover model 31
  - tyrosine kinase receptors 12, 13
  - tyrosine kinases 12, 13
- U**
- Umbrella Organisation of the Statutory Health Insurers (GKV-SV) 248, 250, 251
  - umbrella trials 173
  - unbiased (hypothesis-free) approach 68
  - unique selling point (USP) 103, 110, 141
  - unique selling proposition 141
  - usability engineering team 208
  - user needs 211, 216
- V**
- vaccinia 378
  - validated language 166
  - validation of platform 335
  - value-added benefits 243
  - value assessment 229–231
  - value-based approach 243
  - value-based pricing (VBP) 225, 231, 235–236, 242
    - demand for 242
  - venture debt 341
  - venture financing 338–339
  - venture philanthropy 339
  - virtual screening 50
    - ligand-based 50
    - structure-based 50–51
  - virus neutralization (VN) 384
  - vitrectomy 350–352
  - voice of customer (VOC) 211
  - voltage-controlled channels 12
  - volume of distribution (V) 22, 29, 30
  - Voluntary Harmonisation Process (VHP) 184
- W**
- work breakdown structure (WBS) 267, 268, 271
  - World Intellectual Property Organization (WIPO) 283, 288, 302, 303
  - written subject information 156, 172















